Bambusa Therapeutics Inc. has filed for an IPO to fund trials of drugs for the treatment of inflammatory diseases. This is reported in the Bambusa press release.
Bank of America Corp., Evercore Inc., UBS Group AG and Cantor Fitzgerald are acting as organizers of the Bambusa stock offering.
The company's largest investors are Salvia Investment, RA Capital Management, BVF Partners, Dawn Biopharma and Hong Kong-based INCE Capital.
Bambusa develops long-acting bispecific antibodies for the treatment of immunological and inflammatory diseases, the market of which is estimated at more than $150 billion and covers skin, respiratory, gastroenterological and autoimmune diseases.
Bambusa previously acquired assets from BioNTech SE, a division that developed drugs for the treatment of atopic dermatitis and other inflammatory diseases, including respiratory and allergic diseases.
Bambusa Therapeutics is a biotech company developing long—acting drugs for the treatment of dermatological, respiratory, gastroenterological and rheumatological diseases. The company is headquartered in Boston, Massachusetts.
Read our Telegram channel "Mergers and Acquisitions. AK&M».
Our channel at MAX is "Mergers and Acquisitions. AK&M».
